Compare Cassava Sciences Inc (FLNA) vs Orion Office REIT Inc (ONL) Price & Performance

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.

ONL trades at $2.17, down 4.41% today, with a bearish technical signal from moving averages but bullish oscillators. The REIT shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Valuation metrics include P/S of 0.88 and P/B of 0.2, suggesting potential undervaluation, while analyst consensus is split evenly between Buy and Hold ratings. Recent news highlights strategic portfolio repositioning and a declared $0.02 dividend for H2-26.

Outlook remains challenged by operational losses and high leverage, though deep asset discounts and strategic reviews may offer turnaround potential. Key risks include sustained negative margins, debt servicing pressures, and office sector headwinds. Investment appeal hinges on execution of repositioning efforts and margin recovery.